$ARRY Will The Short Squeeze Continue on Array Biopharma?With Array Biopharma earnings this week, the chance of another short squeeze increases, but so does your risk. Golden Cross on Daily, positive divergence on MACD, riding the upper Bollinger Band as of 8/2. My $ARRY upside target is $5.47 NASDAQ:ARRY
Shortsqueeze
$WTW posible long that could make a nice short squeezeThis stock looks pretty nice for a long swing if we break 16.20, the stock have more than 34% of short interest, if we break that level we should move fast becaouse a lot of people put their stop into tha area
$ATRS recent insider purchase and high short interest$ATRS not my typical play but recent insiders and fairly high short interest
Settlement Date Short Interest Avg Daily Share Volume Days To Cover
3/15/2016 10,444,826 866,786 12.050063
EURUSD: Long term forecast and multitimeframe analysisIn this chart I illustrate the different facets of the trend in the Euro.
It's clear to me that we're about to witness a large short squeeze rally, as evidenced by the following technical landmarks:
Rgmov is moving up in the weekly and daily, not validating the recent decline (which also happened during very low liquidity sessions)
There's a potential time at mode uptrend in the weekly and daily, which can start to work in the coming week. Targets for it match a monthly range expansion validation target roughly, and it sits right below the low volume resistance (which also matches a 0.618 retracement of the whole decline since the 2014 high where this leg started to the lowest low)
Majority of retail bears, but commercials are net long
Weekly moving averages of the lows and highs tell a vivid story, with lows not moving under the low MA and the highs about to be taken out, this usually precedes a breakout.
In the big picture, fundamentals for Europe and the United States show a divergent monetary policy, with the potential for a very bearish outcome for Europe, with the expectation of further easing as the situation is worsened by separatist movements, war, overall poor economic indicators, and a series of rate hikes for the dollar. I can determine if the rally was a short squeeze after the fact as well, so I'll be paying close attention to unleash the perfect short when the time is right.
The bond market is showing an increase of yields is expected in the near term, with bearish price charts for BUXL and US T-Bonds, which adds more fuel to the short squeeze rally thesis as well.
As for the stock market, going by Tim West's long term forecast of sideways and not clearly bullish acitivity, it's only natural to see short term bearish dollar as well.
To add more to my thesis here, there is a quarterly range expansion bar target that wasn't reached in time, which implicates a potential rally to start off this zone. I don't think we will cross the low volume resistance, and I expect to see bearish continuation once the daily uptrend time and price targets are met.
I will give signals to take advantage of this very interesting pair to my private group, if interested in learning more about it contact me via private message.
Cheers,
Ivan Labrie.
Time at Mode FX
GENE great buying opportunityStart of a long term, high profit trend. Has continued short interest in the face of reg-sho forced buybacks (buy-ins), brokers are forcing people to cover at a loss and now have the stock on not able to borrow lists. At historically low levels with support and high bullish volume. Reward to risk favors the longs, a wise portfolio investment.
Short term squeezeLooks like the market is about to get squeezed down below the breakout zone. It will probably stop anywhere from $200 to $210 next. We have a large downward channel acting as the top of a descending triangle that will take us to the low $200s. We had a failed H&S that took us to $245 where we were stopped by the lower end of the breakout zone before the big parabolic move.
This is a pretty safe trade with a decent R/R and high probability, although it is not that big. Given that the trend is still down, it is the safest bet right now.
If you love my ideas, then I love you. BTC donations:
1Eg1QK5vJVCcSoZM3Cp8dgpJ9jv4tjng8m
40% Short squeeze setup on toy maker JAKK with hottest toy of yr40% short interest 30+ days to cover, and several buy signals shaping up. Bullish MACD Cross, Stochastics, and breaking out of a steep downtrend. New 3 month closing highs after retaking both the 50 day and 200 day moving averages this week. Weekly PAR SAR just printed bullish as well. Would jump in or add on the break of $7.50. On a fundamental basis they completed a restructuring and trade at a steep discount to peers Mattel and Hasbro. Takeover candidate as well.
GoPro Goes Berserk For detailed commentary and analysis, see our blog post published 10/3/14: www.syncubate.com
In this post, we'll dissect the stock's surreal run up from the low $50s in the beginning of September to its near-term high of $96.45 on 9/30/14.
Our chart as published on our blog represents two time frames of interest to us from a price action standpoint. The first is the daily time frame for GPRO going back to mid-July. The second is the 30 minute time frame from 9/23 - 10/2.
This post articulates two reasons for the run up in price, and offers a great example of supply versus demand in effect. For more analyses and commentary on the stock market, check out our blog: www.syncubate.com
ACRX- 9 on the horizonContinuing coverage of ACRX this week, we saw ACRX pullback with the market as a whole early this morning. ACRX broke right through support at the .236 retrace, but found support at yesterdays congested zone at the .382 retrace. Uptrend remains in place. $9 remains 1st target. Stop now at 7.70.
ACRX- Short Squeeze AlertPosted a chart on ACRX earlier in the day as a possible short squeeze. ACRX rallied 4% since the posting. Please refer to my earlier chart for analysis.
Short Squeeze? Small Biotech- ACRXAfter getting hammered in July from the FDA delaying approval on its' latest drug for pain relief, Bears have been piling on making an incredible 20% of the float short. Recent buy ratings from analysts could be the catalyst to get a short squeeze going to begin filling the gap left from the huge 40%+ drop in July. If momentum can carry the stock past 8, then 9 is a real possibility in a short amount of time. Two analysts have a hold rating while seven analysts have a buy rating including Jefferies Group that has a price target of $16.